Cromos Pharma, where the patients are

Takeda

Annalisa Jenkins named IIR Partnerships’ Woman of the Year

Tuesday, April 1, 2014 01:43 PM

Annalisa Jenkins, former executive vice president, head of global R&D at Merck Serono, has been named IIR Partnerships’ Woman of the Year.

More... »

CRF Health eCOA webinar series

CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

Wednesday, February 26, 2014 01:21 PM

The Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer's Platform (GAP), designed to reduce the time and costs of Alzheimer's clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

More... »


NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

goBalto expands internationally

Monday, January 13, 2014 11:48 AM

goBalto, a provider of clinical study start-up solutions, has opened its first international locations, in Singapore and the U.K.

More... »

FutuRx begins operations in Israel

Monday, January 13, 2014 11:45 AM

FutuRx Incubator, formerly BioBoost, which has been granted a license by Israel's Ministry of Economy to establish a biotech incubator in Israel, began operations Jan. 1 at the Weizmann Science Park in Ness Ziona. Thirty to 40 startup companies are planned to be established during the next eight years. FutuRx was incorporated jointly by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development (JJDC) and Takeda Pharmaceutical through its corporate venture arm Takeda Ventures.

More... »

Takeda, Sunovion present positive data for Schizophrenia treatment

Tuesday, October 15, 2013 10:39 AM

With educational financial support provided by Takeda and Sunovion Pharmaceuticals Europe, new data has been presented which shows both short and long-term efficacy for lurasidone, an atypical antipsychotic treatment for schizophrenia. These data also showed lurasidone to have early separation from placebo, a rapid onset of action, a favorable side effect profile and to be a well-tolerated, efficacious option for patients with schizophrenia switching medication. Lurasidone has been approved in U.S., Canada and Switzerland and currently is under regulatory review in Europe.

More... »

Takeda terminates agreement with Immunomedics

Friday, October 11, 2013 02:17 PM

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, has received notification from Takeda Pharmaceutical of the termination of the licensing agreement signed between Nycomed and Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20 antibody, for all non-cancer indications.

More... »

Takeda expands to Peru

Friday, August 23, 2013 12:22 PM

Zurich-based Takeda Pharmaceuticals International has further expanded its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

More... »

Former Millennium CEO Deborah Dunsire joins EnVivo as president and CEO

Friday, July 12, 2013 01:57 PM

EnVivo Pharmaceuticals, developing a range of novel therapies for central nervous system (CNS) diseases, has named Deborah Dunsire, M.D., president and chief executive officer. She also joins the company's board of directors. Dunsire brings more than 25 years of scientific, clinical, operational and commercial experience and biological and pharmaceutical industry leadership to EnVivo.

More... »

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs